カテゴリー： 世界, 医療/バイオ, Allied Market Research

世界のアテローム性動脈硬化症治療薬市場2023年-2032年：薬剤種類別（抗血小板薬＆抗凝固薬、コレステロール低下薬、ACE阻害薬、その他）、投与経路別（経口、注射）、流通チャネル別（病院薬局、オンラインプロバイダー、ドラッグストア＆小売薬局）

【英語タイトル】Atherosclerosis Drugs Market By Drug Type (Anti-platelet and Anticoagulants, Cholesterol Lowering Medication, ACE Inhibitors, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

Allied Market Researchが出版した調査資料（ALD23SEP122）・商品コード：ALD23SEP122
・発行会社（調査会社）：Allied Market Research
・発行日：2023年4月
・ページ数：250
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：生命科学
◆販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

アテローム性動脈硬化症治療薬市場は、2022年に206億851万ドルと評価され、2023年から2032年までの年平均成長率は3%で、2032年には277億1192万ドルに達すると推定されています。 アテローム性動脈硬化症は、プラークの蓄積によって静脈が狭くなり、動脈壁が硬化する疾患です。血管に蓄積したプラークによって血流が妨げられ、血圧が上昇します。この状態では、血液中に血栓が形成されることが一般的で、さらに心臓発作、冠動脈疾患、または末梢動脈疾患につながる可能性があります。

アテローム性動脈硬化症治療薬は、コレステロール値を下げ、炎症を抑え、血栓を予防し、血流を改善することで、プラークの形成や体への影響を抑えることを目的としています。一般的に使用されるアテローム性動脈硬化症治療薬には、血栓を予防するアスピリンなどの抗血小板薬、血圧を下げるアンジオテンシン変換酵素（ACE）阻害薬、血圧を維持しながら心臓発作のリスクを最小限に抑えるβ遮断薬などがあります。

世界のアテローム性動脈硬化症治療薬市場の成長は、心血管障害の憂慮すべき増加が主な要因です。また、アテローム性動脈硬化症の早期診断と治療に対する意識の高まりがアテローム性動脈硬化症治療薬の需要を押し上げ、市場の成長にプラスの影響を与えます。 しかし、アテローム性動脈硬化症治療薬の研究開発に関連するコストの急増は、市場の成長を阻害すると予想されます。これとは対照的に、公共部門だけでなく民間部門でも新薬治療への投資が急増しており、予測期間中のアテローム性動脈硬化症治療薬市場の成長に有利な機会を提供すると予想されます。

さらに、先進国と発展途上国の両方における医療費の増加は、医療提供者が最新かつ最も効果的な治療を患者に提供しようとするため、アテローム性動脈硬化症治療薬の需要を促進します。
世界のアテローム性動脈硬化症治療薬市場は、薬剤タイプ、投与経路、流通チャネル、地域に区分されます。薬剤タイプ別では、抗血小板・抗凝固薬、コレステロール低下薬、ACE阻害薬、その他に分類されます。投与経路では、経口剤と注射剤に二分されます。流通チャネル別では、病院薬局、オンラインプロバイダー、ドラッグストア・小売薬局に分類されます。

地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他の欧州地域）、アジア太平洋地域（日本、中国、オーストラリア、インド、韓国、その他のアジア太平洋地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他のLAMEA地域）で分析しています。
本レポートは、世界のアテローム性動脈硬化症治療薬市場で事業を展開する主要企業の包括的な分析を提供します。本レポートに掲載されている主要企業は、Amgen Inc.、Pfizer Inc.、AstraZeneca、Bayer AG、Sanofi、Novartis AG、Viatris、Johnson & Johnson、Lupin、Bausch Health Companies Inc.などです。

ステークホルダーにとっての主なメリット
本レポートは、2022年から2032年までのアテローム性動脈硬化症治療薬市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、アテローム性動脈硬化症治療薬の市場機会を特定します。
主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
アテローム性動脈硬化症治療薬市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
アテローム性動脈硬化症治療薬の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

主要市場セグメント
薬剤タイプ別
抗血小板薬および抗凝固薬
コレステロール低下薬
ACE阻害薬
その他

投与経路別
経口剤
注射剤

流通経路別
病院薬局
オンラインプロバイダー
ドラッグストア・小売薬局

地域別
北米
米国
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
その他の地域

主要市場プレイヤー
○ Amgen Inc.
○ AstraZeneca
○ Bausch Health Companies Inc.
○ Bayer AG
○ Johnson & Johnson
○ Lupin
○ Novartis AG
○ Pfizer Inc.
○ Sanofi
○ Viatris Inc.

第1章：イントロダクション
第2章：エグゼクティブサマリー
第3章：市場概要
第4章：アテローム性動脈硬化症治療薬市場、薬剤タイプ別
第5章：アテローム性動脈硬化症治療薬市場、投与経路別
第6章：アテローム性動脈硬化症治療薬市場、流通チャネル別
第7章：アテローム性動脈硬化症治療薬市場、地域別
第8章：競争状況
第9章：企業情報

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in obesity in populace
3.4.1.2. Increase in government initiatives to promote healthy lifestyle
3.4.1.3. Development of new treatments for atherosclerosis

3.4.2. Restraints
3.4.2.1. Side effects of atherosclerosis drugs

3.4.3. Opportunities
3.4.3.1. Growth opportunities in the emerging markets

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Anti-platelet and Anticoagulants
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Cholesterol Lowering Medication
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. ACE Inhibitors
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Injectable
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Online Providers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Drug Stores and Retail Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: ATHEROSCLEROSIS DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drug Type
7.2.3. Market size and forecast, by Route of Administration
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drug Type
7.2.5.1.3. Market size and forecast, by Route of Administration
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drug Type
7.2.5.2.3. Market size and forecast, by Route of Administration
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drug Type
7.2.5.3.3. Market size and forecast, by Route of Administration
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drug Type
7.3.3. Market size and forecast, by Route of Administration
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drug Type
7.3.5.1.3. Market size and forecast, by Route of Administration
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drug Type
7.3.5.2.3. Market size and forecast, by Route of Administration
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drug Type
7.3.5.3.3. Market size and forecast, by Route of Administration
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drug Type
7.3.5.4.3. Market size and forecast, by Route of Administration
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drug Type
7.3.5.5.3. Market size and forecast, by Route of Administration
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drug Type
7.3.5.6.3. Market size and forecast, by Route of Administration
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drug Type
7.4.3. Market size and forecast, by Route of Administration
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drug Type
7.4.5.1.3. Market size and forecast, by Route of Administration
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drug Type
7.4.5.2.3. Market size and forecast, by Route of Administration
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drug Type
7.4.5.3.3. Market size and forecast, by Route of Administration
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. India
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drug Type
7.4.5.4.3. Market size and forecast, by Route of Administration
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drug Type
7.4.5.5.3. Market size and forecast, by Route of Administration
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drug Type
7.4.5.6.3. Market size and forecast, by Route of Administration
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drug Type
7.5.3. Market size and forecast, by Route of Administration
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drug Type
7.5.5.1.3. Market size and forecast, by Route of Administration
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drug Type
7.5.5.2.3. Market size and forecast, by Route of Administration
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drug Type
7.5.5.3.3. Market size and forecast, by Route of Administration
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drug Type
7.5.5.4.3. Market size and forecast, by Route of Administration
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Amgen Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Pfizer Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. AstraZeneca
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Bayer AG
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Sanofi
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Novartis AG
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Viatris Inc.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Bausch Health Companies Inc.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Lupin
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Johnson & Johnson
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 02. ATHEROSCLEROSIS DRUGS MARKET FOR ANTI-PLATELET AND ANTICOAGULANTS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. ATHEROSCLEROSIS DRUGS MARKET FOR CHOLESTEROL LOWERING MEDICATION, BY REGION, 2022-2032 ($MILLION)
TABLE 04. ATHEROSCLEROSIS DRUGS MARKET FOR ACE INHIBITORS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. ATHEROSCLEROSIS DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 07. ATHEROSCLEROSIS DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 08. ATHEROSCLEROSIS DRUGS MARKET FOR INJECTABLE, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 10. ATHEROSCLEROSIS DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 11. ATHEROSCLEROSIS DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. ATHEROSCLEROSIS DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. ATHEROSCLEROSIS DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 18. U.S. ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 19. U.S. ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 20. U.S. ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 21. CANADA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 22. CANADA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 23. CANADA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 24. MEXICO ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 25. MEXICO ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 26. MEXICO ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 27. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 28. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 29. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 30. EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 31. GERMANY ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 32. GERMANY ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 33. GERMANY ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. FRANCE ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 35. FRANCE ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 36. FRANCE ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 37. UK ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 38. UK ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 39. UK ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 40. ITALY ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 41. ITALY ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 42. ITALY ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 43. SPAIN ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 44. SPAIN ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 45. SPAIN ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 53. JAPAN ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 54. JAPAN ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 55. JAPAN ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 56. CHINA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 57. CHINA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 58. CHINA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 59. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 62. INDIA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 63. INDIA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 64. INDIA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 71. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 72. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 73. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 74. LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 75. BRAZIL ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 76. BRAZIL ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 77. BRAZIL ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA ATHEROSCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 87. AMGEN INC.: KEY EXECUTIVES
TABLE 88. AMGEN INC.: COMPANY SNAPSHOT
TABLE 89. AMGEN INC.: PRODUCT SEGMENTS
TABLE 90. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 91. AMGEN INC.: KEY STRATERGIES
TABLE 92. PFIZER INC.: KEY EXECUTIVES
TABLE 93. PFIZER INC.: COMPANY SNAPSHOT
TABLE 94. PFIZER INC.: PRODUCT SEGMENTS
TABLE 95. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 96. ASTRAZENECA: KEY EXECUTIVES
TABLE 97. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 98. ASTRAZENECA: PRODUCT SEGMENTS
TABLE 99. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 100. ASTRAZENECA: KEY STRATERGIES
TABLE 101. BAYER AG: KEY EXECUTIVES
TABLE 102. BAYER AG: COMPANY SNAPSHOT
TABLE 103. BAYER AG: PRODUCT SEGMENTS
TABLE 104. BAYER AG: PRODUCT PORTFOLIO
TABLE 105. BAYER AG: KEY STRATERGIES
TABLE 106. SANOFI: KEY EXECUTIVES
TABLE 107. SANOFI: COMPANY SNAPSHOT
TABLE 108. SANOFI: PRODUCT SEGMENTS
TABLE 109. SANOFI: PRODUCT PORTFOLIO
TABLE 110. SANOFI: KEY STRATERGIES
TABLE 111. NOVARTIS AG: KEY EXECUTIVES
TABLE 112. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 113. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 114. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 115. NOVARTIS AG: KEY STRATERGIES
TABLE 116. VIATRIS INC.: KEY EXECUTIVES
TABLE 117. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 118. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 119. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 120. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES
TABLE 121. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
TABLE 122. BAUSCH HEALTH COMPANIES INC.: PRODUCT SEGMENTS
TABLE 123. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
TABLE 124. LUPIN: KEY EXECUTIVES
TABLE 125. LUPIN: COMPANY SNAPSHOT
TABLE 126. LUPIN: PRODUCT SEGMENTS
TABLE 127. LUPIN: PRODUCT PORTFOLIO
TABLE 128. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 129. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 130. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 131. JOHNSON & JOHNSON: PRODUCT PORTFOLIO

★調査レポート[世界のアテローム性動脈硬化症治療薬市場2023年-2032年：薬剤種類別（抗血小板薬＆抗凝固薬、コレステロール低下薬、ACE阻害薬、その他）、投与経路別（経口、注射）、流通チャネル別（病院薬局、オンラインプロバイダー、ドラッグストア＆小売薬局）] (コード：ALD23SEP122)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のアテローム性動脈硬化症治療薬市場2023年-2032年：薬剤種類別（抗血小板薬＆抗凝固薬、コレステロール低下薬、ACE阻害薬、その他）、投与経路別（経口、注射）、流通チャネル別（病院薬局、オンラインプロバイダー、ドラッグストア＆小売薬局）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の筋骨格系障害（MSD）治療薬市場2023年-2032年：薬剤種類別（鎮痛薬、DMARD、コルチコステロイド、その他）、投与経路別（経口、非経口）、流通チャネル別（病院薬局、オンラインプロバイダー、ドラッグストア、小売薬局）
  • 世界の血栓溶解薬市場2023年-2032年：製品別（血栓溶解薬、抗血小板薬、抗凝固薬、その他）、疾患別（肺塞栓症、深部静脈血栓症、心房細動、その他）、投与経路別（経口、注射）、流通チャネル別（病院薬局、オンライン薬局、小売薬局）
  • 世界のインクレチン系薬剤市場2023年-2032年：薬剤クラス別（GLP-1受容体作動薬、DPP-4阻害薬）、投与経路別（非経口、経口）、流通チャネル別（病院薬局、ドラッグストア・小売薬局、オンラインプロバイダー）
  • 世界の僧帽弁疾患治療薬市場2023年-2032年：薬剤クラス別（ベータ遮断薬、利尿薬、抗凝固薬、その他）、年齢層別（55歳以下、55歳以上）、流通チャネル別（病院薬局、ドラッグストア＆小売薬局、オンラインプロバイダー）
  • 世界の動脈硬化治療薬市場2023-2033：薬効分類別（抗血小板薬、コレステロール低下薬、βブロッカー、ACE阻害薬、カルシウム拮抗薬、利尿薬）、流通チャネル別（小売薬局、病院薬局、オンライン薬局）、地域別
  • 世界のペニシリン薬市場2023年-2032年：供給源別（天然ペニシリン、半合成ペニシリン）、投与経路別（経口、非経口）、活性スペクトル別（狭域スペクトルペニシリン、広範スペクトルペニシリン、拡張スペクトルペニシリン）、流通チャネル別（病院薬局、ドラッグストア、小売薬局）、オンラインプロバイダー）
  • 世界のマクロライド系抗生物質市場2023年-2032年：薬剤タイプ別（アジスロマイシン、エリスロマイシン、その他）、投与経路別（経口剤、非経口剤、その他）、疾患別（呼吸器感染症、皮膚感染症、性感染症、消化器感染症、その他）、流通チャネル別（病院薬局、ドラッグストア・小売薬局、オンラインプロバイダー）
  • 世界のジストニア治療薬市場2021-2031：薬剤種類別（ドーパミン作動薬、GABA作用薬、抗けいれん薬、その他）、投与経路別（経口、注射）、流通チャネル別（病院内薬局、オンラインプロバイダー、ドラッグストア・小売薬局）
  • 世界の抗血小板剤市場2023年-2032年：薬剤クラス別（アデノシン二リン酸（ADP）受容体阻害剤、非可逆的阻害剤シクロオキシゲナーゼ、その他）、投与経路別（経口剤、注射剤）、流通経路別（病院薬局、ドラッグストア・小売薬局、オンラインプロバイダー）
  • 世界の腸チフス治療薬市場2023年-2032年：治療薬種類別（抗生物質、鎮痛薬、その他）、投与経路別（経口、静脈内）、流通経路別（病院薬局、ドラッグストア・小売薬局、オンラインプロバイダー）

    • ◆H&Iグローバルリサーチのお客様（例）◆